Celia Hart

Celia Hart is currently General Partner and member of the executive committee of Supernova. She serves on the boards of several companies. She has more than 20 years’ experience in the chemical and biotechnology sector. Following her chemistry Ph.D. at Oxford University (UK), Celia worked for Cambridge Antibody Technology, UK (now MedImmune) holding different positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in collaboration with international biotechnology and pharmaceutical partners. In France, she assessed new business opportunities for the European Synchrotron Radiation Facility (ESRF) and the Atomic Energy Commission (CEA).